Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
Human narcolepsy is tightly associated with HLA-DQB1*0602; canine narcolepsy is linked with a DNA segment with high homology with the human immunoglobulin mu-switch segment, and the onset of canine narcolepsy is associated with increased microglial expression of major histocompatibility complex DQ and DR molecules.
|
9363189 |
1996 |
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
These results could be explained by increased disease heterogeneity in the noncataplexy group or by a direct effect of the HLA DQB1*0602 genotype on the clinical expression of narcolepsy.
|
9456467 |
1997 |
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
These results indicate that HLA-DQB1*0602 homozygosity increases susceptibility to narcolepsy but does not appear to influence disease severity.
|
9459509 |
1998 |
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
The importance of HLA DQB1*0602 typing in Slovene patients with narcolepsy.
|
12097985 |
2002 |
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
We decided to test for the presence of several neuron-specific and organ-specific autoantibodies to see if they were present in HLA DQB1*0602-associated or cataplexy-associated narcolepsy or could serve as a serologic marker of the illness.
|
12405606 |
2002 |
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
Biological markers of narcolepsy with cataplexy (classical narcolepsy) include sleep-onset REM periods (SOREM) on multiple sleep latency tests (MSLT), HLA-DQB1*0602 positivity, low levels of cerebrospinal fluid (CSF) hypocretin-1 (orexin A), increased body mass index (BMI), and high levels of CSF leptin.
|
14592354 |
2003 |
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
The month-of-birth pattern in narcolepsy is moderated by cataplexy severity and may be independent of HLA-DQB1*0602.
|
15683136 |
2004 |
Narcolepsy
|
0.800 |
Biomarker
|
disease |
LHGDN |
[Diagnosis of childhood narcolepsy and significance of HLA in its diagnosis].
|
15157381 |
2004 |
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Clock gene polymorphisms and narcolepsy in positive and negative HLA-DQB1*0602 patients.
|
16125818 |
2005 |
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
Increased prevalence of HLA-DQB1*0602, a marker of narcolepsy, was observed in males but not in females with > or =2 SOREMPs.
|
16597649 |
2006 |
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
Although narcolepsy presents one of the tightest associations with a specific human leukocyte antigen (HLA) (DQB1*0602), there is strong evidence that non-HLA genes also confer susceptibility.
|
16754256 |
2006 |
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
To quantify T CD4, T CD8 and B lymphocytes in subgroups of patients with narcolepsy and the presence or absence of the HLA-DQB1*0602 allele between groups.
|
17665008 |
2007 |
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
HLA-DQB1*0602 and HLA DRB1 alleles are closely associated with narcolepsy.
|
18345414 |
2007 |
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
The association of narcolepsy with HLA-DQB1*0602 is established in Japanese, African-Americans, European, and North American Caucasians.
|
17207713 |
2007 |
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
The tight co-segregation of HLA DQB1*0602 and narcolepsy spectrum disorders might suggest that HLA typing, especially DQB1*0602, at least partly confer the familial risk of narcolepsy.
|
17682655 |
2007 |
Narcolepsy
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The high frequency of HLA-DQB1*0602, low frequency of HLA-DQB1*0601 and low hypocretin levels in cataplexy-positive groups suggest that cataplexy-positive narcolepsy might be an etiologically different disease entity from the cataplexy-negative.
|
17297265 |
2007 |
Narcolepsy
|
0.800 |
Biomarker
|
disease |
BEFREE |
The cataplectic narcolepsy differed from non-cataplectic narcolepsy by having more rapid eye movement (REM)-related clinical symptoms (more sleep paralysis and sleep-related hallucination) and sleep disturbances (shorter REM latency), as well as tighter association with HLA DQB1*0602.
|
18388176 |
2008 |
Narcolepsy
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
There was no difference in the MX2 expression level between the narcolepsy subjects and the HLA-DQB1 genotype-matched control subjects.
|
18517045 |
2008 |
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Narcolepsy (hypocretin deficiency), a sleep disorder characterized by sleepiness, cataplexy and rapid eye movement (REM) sleep abnormalities, is tightly associated with HLA-DRB1*1501 (M17378) and HLA-DQB1*0602 (M20432).
|
18820697 |
2008 |
Narcolepsy
|
0.800 |
SusceptibilityMutation
|
disease |
ORPHANET |
Association of narcolepsy-cataplexy with HLA-DRB1 and DQB1 in Mexican patients: a relationship between HLA and gender is suggested.
|
18706091 |
2008 |
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Prevalence of the HLA-DQB1*0602 allele in narcolepsy and idiopathic hypersomnia patients seen at a sleep disorders outpatient unit in São Paulo.
|
19506770 |
2009 |
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Passive smoking may be a risk factor for narcolepsy in subjects with HLA DQB1*0602.
|
19039244 |
2009 |
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
For narcolepsy with HLA-DQB1 *0602, prevalence was 15.3 (95% CI: 12.8-17.9).
|
19013100 |
2009 |
Narcolepsy
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Narcolepsy symptom severity varies in a linear manner according to HLA-DQB1*0602 allele status.
|
20120618 |
2010 |
Narcolepsy
|
0.800 |
Biomarker
|
disease |
CTD_human |
Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy.
|
20711174 |
2010 |